<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-17012462</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-08-24</date_registration>
      <primary_sponsor>Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing </primary_sponsor>
      <public_title>Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells combined with recombinant human gamma interferon (IFN-γ) in the treatment of Rheumatoid Arthritis (RA) </public_title>
      <acronym />
      <scientific_title>Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells combined with recombinant human gamma interferon (IFN-γ) in the treatment of Rheumatoid Arthritis (RA) </scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-09-01</date_enrolment>
      <type_enrolment />
      <target_size>treatment group:30;control group:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=21250</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>rheumatoid arthritis </hc_freetext>
      <i_freetext>treatment group:hUC-MSCs, IFN-γ;control group:hUC-MSCs;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Yi Yang</firstname>
        <middlename />
        <lastname />
        <address>10 Changjiang Branch Road, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18502389013</telephone>
        <email>yangyilyx@163.com</email>
        <affiliation>Department of Rheumatology and Immunology, Daping Hospital, Third Military Medical University, Chongqing</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xiang Xu</firstname>
        <middlename />
        <lastname />
        <address>10 Changjiang Branch Road, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 1363784387</telephone>
        <email>xiangxu@ymail.com</email>
        <affiliation>Department of Rheumatology and Immunology, Daping Hospital, Third Military Medical University, Chongqing</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital;
2. Patients of RA, to be aged 18 years to 65 years old;
3. All patients fulfilled the classification criteria (ACR21987) for rheumatoid arthritis;
4. All patients fulfilled hormone-dependent or through formal use of methotrexate / leflunomide / hydroxychloroquine sulfate / sulfasalazine / tripterygium and / or at least one kind of TNF-α inhibitor, is still high disease activity or can not be tolerated. </inclusion_criteria>
      <agemin>18</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patients with uncorrected disease, such as advanced cancer or other terminal illness, the prospective survival period less than 28 days;
2. Patients in the foreseeable dying state;
3. Have the bone marrow, lungs, liver, pancreas, or small bowel transplantation history;
4. Have severe heart and lung failure, or irreversible damage or failure of other major organs;
5. Uncontrolled infection;
6. Patient participating or having participated in a clinical trial with another investigational drug Within 30 days before the start of this clinical trial;
7. Patient is pregnant or nursing;
8. History of patient is allergic to biological products;
9. HIV infected associated with the recent CD4+ cell count ≤50/mm3;
10. viral hepatitis. </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>DAS28;HAQ;CRP;ESR;Treg;Th17;IFN-γ;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-financed</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-09-25</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>